ArticleJournal of clinical pharmacology2026

Population Pharmacokinetics and Exposure-Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non-Muscle Invasive Bladder Cancer and Other Solid Tumors.

Joanna C Masters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.